Levocetirizine
Levocetirizine Dihydrochloride (Xyzal) — Second-Generation Antihistamine (H1 Blocker)
Compelling PGD2-based rationale and consistently positive clinical signals with cetirizine, but no large definitive trial — best used as an adjunct to proven treatments
How Levocetirizine works — and how well we know it
Selective H1 receptor antagonist and mast cell stabilizer. Suppresses PGD2 production from mast cells (PGD2 is elevated in bald scalp and inhibits hair growth via GPR44/DP2 receptor). Simultaneously upregulates pro-hair prostaglandins PGE2 and PGF2a. Reduces perifollicular inflammation and neurogenic mast cell degranulation. Activates AKT signaling pathway in dermal papilla cells.
topical (1% solution, compounded), oral (5 mg tablet, off-label)
Topical: 1% cetirizine/levocetirizine solution applied daily to scalp. Oral: 5 mg levocetirizine (standard allergy dose) — scalp-specific dosing not established.
FDA-approved for allergic rhinitis and chronic urticaria (as Xyzal, 5 mg oral). Not approved for hair loss. Cetirizine (racemic form) is available OTC as Zyrtec. Topical cetirizine 1% is compounded off-label for alopecia.
Adjunct to minoxidil/finasteride; patients with scalp inflammation; those intolerant of first-line treatments
Evidence distribution across 8 claims
Why the grade is C. Strong mechanistic rationale via PGD2/mast cell pathway. Multiple small-to-moderate human trials of topical cetirizine (the racemic form) show positive signals including one double-blind RCT as a combination adjunct. No direct human trial of levocetirizine itself for hair loss. Clinical data is consistently positive but limited by small sample sizes, suboptimal designs, and short durations.
What the trials actually showed
85 subjects (male and female) with androgenetic alopecia
40 men (ages 18-49) with androgenetic alopecia
66 women (ages 20-50) with female pattern hair loss
Males aged 18-49 with androgenetic alopecia
Cultured human dermal papilla cells
Estimated 3-6 months based on the available trial durations (16-24 weeks). The Rossi 2018 trial measured outcomes at 6 months and found significant improvements. The Moneib 2021 trial showed detectable differences at 16 weeks. No data exist on earlier time points. Unlike minoxidil, no 'dread shed' has been reported with cetirizine/levocetirizine.
Unknown. The longest trial duration is 24 weeks (Mostafa 2023). Whether continued use beyond 6 months produces additional gains has not been studied. Hair loss treatments typically need 12-24 months to demonstrate full efficacy.
Yes — must continue indefinitely
Limited data. The Moneib 2021 trial included an 8-week drug-free phase and cetirizine appeared to maintain gains better than minoxidil during this period. However, 8 weeks is too short to draw firm conclusions. The anti-inflammatory mechanism suggests that discontinuation would eventually allow mast cell-mediated inflammation and PGD2 elevation to resume, leading to renewed hair loss — but this is theoretical.
Side effects, contraindications, and special populations
| Adverse event | Rate | Placebo | Notes |
|---|---|---|---|
| Somnolence/drowsiness (oral) | 6% (vs 2% placebo) in allergy trials at 5 mg dose | — | Most common side effect. Levocetirizine is a second-generation antihistamine with reduced CNS penetration compared to first-generation agents, but drowsiness still occurs. A randomized double-blind trial (Day 2011) found sedation was not significantly different between levocetirizine and cetirizine, though some clinical reports suggest levocetirizine may be slightly less sedating. Dose-dependent. Taking at bedtime mitigates this for most patients. |
| Nasopharyngitis (oral) | 4% (vs 3% placebo) in allergy trials | — | Mild and not clearly distinguishable from background rates. Reported in clinical trials but may not be drug-related. |
| Fatigue (oral) | 4% (vs 2% placebo) in allergy trials | — | Overlaps with somnolence. More common at higher doses. Usually mild. |
| Dry mouth (oral) | 2% (vs 1% placebo) in allergy trials | — | Anticholinergic-like effect. Mild in most patients. Less prominent than with first-generation antihistamines. |
| Pharyngitis (oral) | 1% (vs 1% placebo) in allergy trials | — | Essentially equal to placebo. Unlikely to be drug-related. |
| Headache (oral) | Reported in post-marketing; not significantly above placebo in trials | — | Mild and transient when reported. |
| Scalp irritation (topical) | Not formally quantified; reported as minimal across cetirizine hair loss trials | — | Topical cetirizine 1% appears very well tolerated on the scalp. Rossi 2018 reported no notable side effects. Moneib 2021 reported no significant adverse reactions. Mostafa 2023 reported no significant difference in side effects between cetirizine and placebo groups. Compounding vehicle may contribute to any irritation. |
- Urinary retention (Rare; reported in post-marketing surveillance) — Anticholinergic-like effect. May cause incomplete bladder emptying. More likely in elderly men or patients with pre-existing urinary obstruction. Not reported in hair loss populations.
- Severe allergic reactions (anaphylaxis, angioedema) (Extremely rare; isolated post-marketing reports) — Paradoxical given that this is an antihistamine. Exceedingly uncommon. Reported as individual case reports.
- Psychiatric effects (aggression, agitation — pediatric) (Rare; identified in post-marketing pharmacovigilance) — Primarily reported in pediatric patients. Not relevant to typical hair loss population (adults). Mechanism unclear.
- Hepatobiliary disorders (Extremely rare post-marketing reports (hepatitis)) — Isolated case reports only. Levocetirizine is primarily renally excreted, so hepatic effects are uncommon.
- Hypersensitivity to levocetirizine, cetirizine, or any component of the formulation
- End-stage renal disease (creatinine clearance <10 mL/min) — levocetirizine is primarily renally excreted and accumulates in severe renal impairment
- Children aged 6 months to 11 years with renal impairment
- Patients on hemodialysis — levocetirizine is not effectively removed by dialysis
- CNS depressants (alcohol, benzodiazepines, opioids, sedative-hypnotics) (Moderate) — Additive CNS depression. May worsen drowsiness, impaired concentration, and reduced psychomotor performance. Avoid alcohol; use caution with other sedating agents.
- Ritonavir (and other strong CYP3A4 inhibitors) (Moderate) — Ritonavir increased plasma AUC of cetirizine by ~42% with a 53% increase in half-life and 29% decrease in clearance. Though levocetirizine is minimally hepatically metabolized, monitor for increased sedation if co-administered.
- Theophylline (Low) — Small decrease in cetirizine clearance (~16%) observed with theophylline co-administration. Clinical significance is likely minimal at standard levocetirizine doses.
- Anticholinergic agents (Low) — Potential additive anticholinergic effects (dry mouth, urinary retention, constipation). Clinical significance is low because levocetirizine has minimal intrinsic anticholinergic activity.
FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, but there are no adequate, well-controlled studies in pregnant women. Available post-marketing data are insufficient to identify drug-associated risks. Use only if clearly needed. Cetirizine is generally considered one of the preferred second-generation antihistamines in pregnancy by allergist guidelines, but this does not extend to off-label hair loss use.
No sex-specific safety concerns beyond the standard profile. The best hair loss efficacy data (Mostafa 2023 double-blind RCT) was conducted in women, showing additive benefit with minoxidil. Topical cetirizine does not carry the teratogenicity concerns of finasteride. Women of childbearing age can use levocetirizine without contraception requirements (unlike finasteride or dutasteride). The favorable safety profile makes it an attractive adjunct option for women with AGA.
FDA-approved for allergic rhinitis in children 6 months and older (dose-adjusted). Not studied for hair loss in children. Post-marketing reports of aggression and agitation in pediatric patients warrant caution. Hair loss use in children should be approached conservatively.
Every claim, traced back to its source
We took every major claim made about Levocetirizine and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.
8 claims · evidence-by-evidence breakdown
1Ex VivoWeight: Moderate-HighPGD2 is elevated in bald scalp and directly inhibits hair growth through the GPR44 receptorLandmark PGD2 discovery provides the rationale for antihistamine use in AGA, but does not directly test cetirizine/levocetirizine.
Explanted human hair follicles from men with AGA, plus transgenic mouse models (K14-Ptgs2). Published in Science Translational Medicine. Researchers measured PTGDS expression and PGD2 levels in bald vs. haired scalp, tested PGD2 effects on explanted follicles and mouse skin, and characterized the receptor pathway.
PTGDS is elevated at mRNA and protein levels in bald scalp. PGD2 is elevated in bald scalp tissue. Applied PGD2 inhibits hair growth in human follicle explants and in mice. A transgenic mouse with elevated skin PGD2 develops alopecia, follicular miniaturization, and sebaceous gland hyperplasia. Hair growth inhibition requires GPR44 (DP2/CRTH2), not the DP1 receptor.
This is one of the most important discoveries in AGA biology in the last two decades. It established PGD2 as a bona fide inhibitor of hair growth and identified GPR44 as the key mediator. It provides the biological foundation that makes antihistamines like cetirizine and levocetirizine worth investigating — because H1 antihistamines reduce PGD2 release from mast cells. However, this paper does not test cetirizine or levocetirizine. The link is mechanistically logical but indirect.
- Garza LA, Liu Y, Yang Z, et al. (2012). Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia. Sci Transl Med PMID 22440736
2In VitroWeight: LowLevocetirizine promotes dermal papilla cell proliferation by inhibiting PGD2-GPR44 and activating AKT signalingClean in vitro proof-of-concept showing PGD2 suppression and DPC proliferation, but cell culture results frequently fail to translate clinically.
Human dermal papilla cells (hDPCs) cultured with levocetirizine HCl at 1, 10, 100, 1,000, and 10,000 ng/mL for 48 hours. Proliferation measured by MTT assay. mRNA expression of COX-2, PTGDS, PGE2, PGF2a, GPR44, AKT, GSK3b measured by real-time PCR. Protein expression measured by Western blot and ELISA.
At 100 ng/mL, levocetirizine significantly increased hDPC proliferation (115.80% +/- 5.10% vs. 100% control, p<0.05). COX-2, PTGDS, and GPR44 mRNA were significantly reduced; PGF2a and AKT mRNA were significantly increased. PTGDS protein dropped from 0.73 to 0.32, PGD2 dropped from 180.08 to 141.62 pg/mL, and PGD2R dropped from 273.24 to 215.08. pAKT increased from 0.46 to 0.59 and pGSK3b from 0.35 to 0.46.
This is the most important mechanistic study for levocetirizine specifically. The results are biologically coherent: levocetirizine suppresses the PGD2 pathway while upregulating PGF2a and activating AKT signaling. The concentration-response relationship is clean, with 100 ng/mL as the sweet spot. However, cells in a dish lack their 3D niche, blood supply, and hormonal environment. Compounds that stimulate DPC proliferation in vitro do not always translate to hair growth in humans.
- Wen X, Wei P, Wang Y, et al. (2020). Effect of levocetirizine hydrochloride on the growth of human dermal papilla cells: a preliminary study. Ann Palliat Med PMID 32156129
3Open-LabelWeight: Moderate-HighTopical cetirizine 1% increases total and terminal hair density in AGAPositive human data showing the right clinical pattern, but limited by open-label design and small control group.
85 subjects (male and female) with AGA. 67 applied topical cetirizine 1% daily for 6 months; 18 applied vehicle control. Trichoscopic measurement of hair density, terminal/vellus counts, and diameter at baseline and 6 months.
The cetirizine group showed significant increases in total hair density and terminal hair density, with increased diameter variation. Vellus hair density decreased, suggesting vellus-to-terminal conversion. No notable side effects. Good patient compliance.
This is the foundational clinical study for topical cetirizine in AGA and the results are encouraging. The pattern of increased terminal density with decreased vellus density is exactly what clinicians want to see. However, the open-label design means patients and investigators knew who received treatment, which introduces bias. The control group (18 patients) is too small for robust statistical comparison. No standardized global photography was reported. Uses racemic cetirizine, not levocetirizine specifically.
- Rossi A, Campo D, Fortuna MC, et al. (2018). A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Eur Acad Dermatol Venereol PMID 28604133
4RCTWeight: ModerateTopical cetirizine is effective but less potent than minoxidil, with potentially longer-lasting effectsCetirizine produces measurable hair improvements but underperforms minoxidil; may maintain gains better after discontinuation.
40 men aged 18-49 with AGA randomized to topical cetirizine 1% or minoxidil 5% twice daily for 16 weeks (treatment phase), followed by 8 weeks of placebo (drug-free phase). Trichoscopic outcomes: total hair density, vellus/terminal density, hair diameter, anagen/telogen percentages.
Both groups showed significant increases in total and vellus hair density at 16 weeks, but minoxidil produced significantly greater improvements. Both showed increased anagen-phase hairs. During the 8-week drug-free phase, cetirizine appeared to maintain gains better than minoxidil. No significant adverse reactions with cetirizine.
This is the best comparative data available and the results are informative: cetirizine works, but is less potent than minoxidil. The hint of longer-lasting effects post-discontinuation is intriguing, as minoxidil is notoriously dependent on continuous use. However, the single-blind design introduces bias, 20 subjects per arm is underpowered, and the 8-week post-treatment follow-up is too short for firm conclusions about durability. Uses racemic cetirizine.
- Moneib H, Fawzy MM, Youssef SS, Aly DG (2021). Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. J Pharm Pharm Sci PMID 33909554
5RCTWeight: HighAdding topical cetirizine to minoxidil provides additive benefit in female AGAGold-standard RCT showing cetirizine adds measurable benefit on top of minoxidil in female AGA.
66 women aged 20-50 with female pattern hair loss randomized to topical cetirizine 1% plus minoxidil 2% or placebo plus minoxidil 2% for 24 weeks. Trichoscopic measurement of terminal/vellus density, hair shaft thickness, follicular unit density. Patient self-assessment.
Cetirizine + minoxidil showed statistically significant improvements over minoxidil alone in frontal and vertex terminal and vellus hair density (p<0.0005), vertex hair shaft thickness, and average hairs per follicular unit (p<0.05). Patient self-assessment scores were significantly better in the cetirizine group (p<0.05). Side effects were not significantly different between groups.
This is the gold-standard design: double-blind, placebo-controlled. It demonstrates that cetirizine provides additive benefit on top of minoxidil, which is exactly the combination data clinicians need. The 24-week duration is adequate for a preliminary signal. The caveat is that you cannot isolate cetirizine's independent contribution — it may work primarily as a minoxidil enhancer rather than a standalone agent. Also, this was in female AGA, which has different hormonal dynamics than male AGA. Uses racemic cetirizine.
- Mostafa E, El-Gohary RM, El-Banna H, et al. (2023). Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Arch Dermatol Res PMID 36571611
6Ex VivoWeight: ModerateMast cells and perifollicular inflammation contribute to AGA progression, and antihistamines may interrupt this cycleWell-documented pathological link between mast cells and AGA fibrosis, but the therapeutic application of antihistamines through this mechanism is unproven.
Histopathological analysis of human AGA scalp biopsies from multiple research groups, plus animal models of neurogenic inflammation involving substance P and mast cell degranulation.
AGA scalps show increased perifollicular mast cell numbers correlating with fibrosis severity. Mast cells release histamine, proteases, PGD2, and pro-inflammatory cytokines promoting perifollicular fibrosis. In animal models, neurogenic inflammation triggers mast cell degranulation and premature catagen induction. The histamine-synthesizing enzyme histidine decarboxylase increases during hair cycle initiation.
The mast cell/fibrosis connection in AGA is well-documented by multiple research groups. The idea that dampening mast cell activity with antihistamines could slow or partially reverse this process is biologically plausible. However, no study has directly shown that H1 blockade reverses perifollicular fibrosis in human AGA or that this mechanism is responsible for the clinical benefits seen with topical cetirizine.
- Mahemuti N, et al. (2008). Dermal fibrosis in male pattern hair loss: a suggestive implication of mast cells. Arch Dermatol Res PMID 18286292
- Paus R, et al. (2006). Neurogenic Inflammation in Stress-Induced Termination of Murine Hair Growth Is Promoted by Nerve Growth Factor. Am J Pathol
7In VivoWeight: Low to ModerateLevocetirizine nanoparticle formulation shows enhanced skin deposition in ratsPromising drug delivery data showing enhanced skin penetration, but no hair growth outcomes were measured.
Levocetirizine HCl loaded into cationic ceramide/phospholipid composite nanoparticles (CCPCs). In silico molecular docking against PGD2 receptors. Optimized formulation tested via ex vivo skin permeation and in vivo dermatokinetic studies in rats.
In silico docking confirmed levocetirizine binding to PGD2 receptor targets. Optimized nanoparticles (88.36% entrapment efficiency, 479 nm particle size) achieved significantly greater skin deposition than levocetirizine solution. In vivo rat studies confirmed enhanced drug deposition from the nanoparticle carrier. No histological skin alterations or irritation observed.
This study addresses a practical question: can you deliver enough levocetirizine into scalp skin to be therapeutic? The nanoparticle formulation clearly outperforms a simple solution for drug deposition. The in silico work supports PGD2 receptor engagement. However, this is a drug delivery and safety study — it did not measure any hair growth endpoints. It demonstrates the drug gets into rat skin, not that it regrows hair.
- Elsewedy HS, Shehata TM, Soliman WE, et al. (2022). Repurposing levocetirizine hydrochloride loaded into cationic ceramide/phospholipid composite (CCPCs) for management of alopecia. Drug Deliv PMID 36047012
8RCTWeight: ModerateThe PGD2 receptor antagonist setipiprant failed in a Phase 2a trial — important context for the PGD2 hypothesisSelective PGD2 receptor blockade failed, but cetirizine/levocetirizine works through broader mechanisms that may explain its positive clinical signals.
Males aged 18-49 with AGA randomized to oral setipiprant 1000 mg twice daily or placebo for 24 weeks in a double-blind, multicenter Phase 2a trial. Week 32 follow-up.
Setipiprant was safe and well tolerated but did not demonstrate efficacy versus placebo on any hair growth endpoint.
This negative result is important context. Setipiprant selectively blocks GPR44/CRTH2, the exact receptor Garza et al. identified. Its failure suggests PGD2-GPR44 blockade alone is insufficient for hair regrowth. However, this does not invalidate the antihistamine approach because cetirizine/levocetirizine works through broader mechanisms: H1 blockade, mast cell stabilization, PGE2/PGF2a upregulation — effects that a pure GPR44 blocker does not provide. The in vitro data on levocetirizine showed simultaneous PGD2 suppression and PGF2a upregulation, a duality setipiprant cannot achieve. Alternative explanations include inadequate scalp drug levels from oral dosing, or insufficient treatment duration.
- Blume-Peytavi U, Vogt A, Gollnick H, et al. (2021). Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial. Clin Cosmet Investig Dermatol
What's still missing from the science
- A human clinical trial of levocetirizine specifically for hair loss. All existing clinical data uses racemic cetirizine. While levocetirizine is the active enantiomer and pharmacologically equivalent at half the dose, this has not been confirmed in a hair loss context.
- A large, well-powered RCT of topical cetirizine as monotherapy vs. placebo in male AGA. The best existing placebo-controlled data is a combination study (cetirizine + minoxidil vs. minoxidil alone in female AGA).
- Long-term data beyond 24 weeks. Hair loss treatments typically need 12-24 months to demonstrate full efficacy and maintenance.
- A systematic dose-finding study for topical cetirizine/levocetirizine. The 1% concentration used across studies was not established through dose optimization.
- Direct evidence that antihistamine use reverses perifollicular fibrosis in human AGA — the mast cell mechanism is pathologically documented but therapeutically unconfirmed.
- Head-to-head comparison of oral vs. topical administration for hair outcomes to determine whether systemic H1 blockade at standard allergy doses achieves meaningful scalp PGD2 suppression.
Our verdict on Levocetirizine
Where levocetirizine shows up
We don't sell topical levocetirizine on its own — but you'll find it in every multi-active topical we make.
From the Anagen blog
Long-form analysis and primary-source breakdowns that go beyond the summary above.
Related treatments
How does Levocetirizine stack up against its closest peers?
Most potent 5-alpha reductase inhibitor with RCT evidence of superiority over finasteride.
Read the breakdown →Well-tolerated adjunct with antifungal, anti-inflammatory, and potential anti-androgenic properties.
Read the breakdown →Strong prostaglandin biology and one small positive RCT for scalp, but validated only for eyelash growth (via bimatoprost/Latisse)
Read the breakdown →